For instance, the dominant enrichment of GM-CSF in metastatic tumors suggests that it could be a promising target for therapeutic antibodies or small molecule inhibitors, potentially improving patient outcomes by disrupting the immunosuppressive tumor microenvironment. This evidence concerns the gene CSF2 and metastatic neoplasm.